Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2010

View Archived Issues

Greater blood pressure reduction seen with LCZ-696 than with valsartan in hypertension

Pfizer describes identification of selective 5-HT6 receptor antagonist WAY-262531

Preclinical safety of oseltamivir supports clinical development in infants

Studies describe pharmacokinetics, interactions with renin inhibitor ACT-178882/MK-1597

GLY-230 may ameliorate renal disease in patients with diabetes

Discovery of HCV protease inhibitor BMS-650032 described

Targacept presents novel nicotinic acetylcholine alpha4beta2 receptor ligands

UHN claims new triazolium and imidazolium salts for treatment of parasitic infections

Repligen discovers novel HDAC3 inhibitors

Emory University claims new noscapine analogues for cancer therapy

Addex and Ortho-McNeil-Janssen claim positive allosteric mGlu2 modulators

Patient enrollment initiated in phase II study of Reolysin for SCC lung cancer

Emory University and Zirus enter a collaboration and research agreement to create new antivirals

SciClone reports topline phase II data on SCV-07 for prevention of oral mucositis

FDA issues complete response letter on AstraZeneca and Abbott's Certriad NDA for mixed dyslipidemia

FDA approves Asclera for treatment of small varicose veins

Eisai submits anticancer agent eribulin for approval in Japan, U.S. and Europe

Banyu submits V-260 rotavirus vaccine for approval in Japan

BioDiem provides update on pandemic influenza vaccine program

NexMed files IND with FDA for phase II trial of PrevOnco in hepatocellular carcinoma

Action Pharma completes dosing in phase II AP-214 trial

FDA accepts voclosporin NDA for priority review

YM BioSciences expands ongoing phase I/II CYT-387 study in myelofibrosis

Titan begins phase III study of Probuphine in opioid addiction

PolyMedix completes phase Ib trial of novel antibiotic PMX-30063

Critical Outcome Technologies reports preclinical data on oral COTI-2 in TNBC model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026